伊曲康唑治疗严重烧伤患者真菌感染的疗效分析

Efficacy and safety of itraconazole in the treatment of deep fungal infections in severe burn patients

目的评价伊曲康唑治疗严重烧伤患者真菌感染的疗效及其安全性。方法采用开放、随机研究单组评估设计治疗前2d:伊曲康唑注射液2次/d,间隔12h,200mg/次。此后1次/d,剂量200mg,间隔24h,1疗程14d。试验结束后口服伊曲康唑口服液维持治疗至少4周,2次/d,200mg/次。结果伊曲康唑治疗23例严重烧伤患者总有效率为60.87%本组86.96%的患者临床疗效为改善;63.64%的患者真菌学疗效为真菌清除;8.70%和52.17%的患者综合疗效分别为痊愈和显效,未发生不良反应。结论伊曲康唑治疗严重烧伤患者真菌感染有良好的疗效、不良反应少。

Objective To evaluate the efficacy and safety of itraconazole treating deep fungal infections in severe burn patients. Methods An open randomized trial was performed to access the cure rates of severe burn patients with deep fungal infections. A total of 23 burn patients who had proven or suspected deep fungal infections were enrolled in this study. Each patient was administered itraconazole （dosage ：200 mg） at least 60 minutes twice in the first two days, then once a day in the following 3 ～ 14 days ,followed by consecutive itraconazole（ 200 mg, Bid,p. o.） treatment for the next 4 weeks. Results Total clearance was about 60.87%, clinical efficacy was 86.96%, fungal clearance was 63.64%. Most patients experienced relief from clinical infectious symptoms, signs and systemical reactions. No adverse drug reaction occurred during this study. Conclusion Itraconazole was effective and safe in the treatment of deep fungal infections in severe burn patients.